ORNELA IKA: Open Payments
NPI 1477338291 · FLORISSANT, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,253 in 70 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $57 · 2025 $1,253
Food & beverage: $1,253
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 24 | $439 |
| E.R. Squibb & Sons, L.L.C. | 17 | $235 |
| Lundbeck LLC | 4 | $101 |
| Otsuka America Pharmaceutical, Inc. | 4 | $78 |
| Alkermes, Inc. | 3 | $71 |
| Luye Pharma (USA) Ltd. | 3 | $66 |
| Teva Pharmaceuticals USA, Inc. | 4 | $63 |
| Vanda Pharmaceuticals Inc. | 3 | $56 |
| ABBVIE INC. | 2 | $41 |
| Neurocrine BioSciences, Inc. | 2 | $33 |
Products named: CAPLYTA, COBENFY, REXULTI, ABILIFY MAINTENA, ERZOFRI EXTENDED-RELEASE, UZEDY, FANAPT, ARISTADA.
Industry payments across MO — which companies pay providers there.
